GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ULTA · Apr 29, 2017

Ulta Beauty, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-17-191202General Corporate
Capex intensity15thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

5.84% · OPTIONAL · VALID

Revenue growth60thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

22.46% · CORE · VALID

Gross margin70thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

36.20% · CORE · VALID

Operating margin100thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

14.33% · CORE · VALID

SBC intensity25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.42% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History62 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
7.70%
Current
5.84%
Delta
-1.86%
Growth Decreased
Previous
23.72%
Current
22.46%
Delta
-1.25%
Margin Increased
Previous
35.99%
Current
36.20%
Delta
0.21%
Profitability Increased
Previous
13.49%
Current
14.33%
Delta
0.84%
Sbc Intensity Increased
Previous
0.40%
Current
0.42%
Delta
0.02%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.